Zhou X - Search Results

1

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.

Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, Zhou W, Yan Y, Zhou X, Zhang J. Su C, et al. Among authors: zhou x, zhou w. Front Oncol. 2020 Sep 17;10:554313. doi: 10.3389/fonc.2020.554313. eCollection 2020. Front Oncol. 2020. PMID: 33072580 Free PMC article. Review.

2

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing.

Chen XZ, Guo R, Zhao C, Xu J, Song H, Yu H, Pilarsky C, Nainu F, Li JQ, Zhou XK, Zhang JY. Chen XZ, et al. Front Pharmacol. 2022 Jul 22;13:939090. doi: 10.3389/fphar.2022.939090. eCollection 2022. Front Pharmacol. 2022. PMID: 35935840 Free PMC article. Review.

3

Oxidized LDL promotes EMS-induced angiogenesis by increasing VEGF-A expression and secretion by endometrial cells.

Ma C, Huang W, Wang H, Yao W, Liang M, Yu G, Zhou X. Ma C, et al. Among authors: zhou x. Mol Med. 2022 Dec 12;28(1):151. doi: 10.1186/s10020-022-00582-6. Mol Med. 2022. PMID: 36503493 Free PMC article.

4

CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.

Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF, Xie D. Li Y, et al. Cell Death Dis. 2019 Feb 4;10(2):99. doi: 10.1038/s41419-019-1371-1. Cell Death Dis. 2019. PMID: 30718500 Free PMC article.

5

TCR-like antibodies in cancer immunotherapy.

He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J. He Q, et al. Among authors: zhou x. J Hematol Oncol. 2019 Sep 14;12(1):99. doi: 10.1186/s13045-019-0788-4. J Hematol Oncol. 2019. PMID: 31521180 Free PMC article. Review.

6

Targeting cancers through TCR-peptide/MHC interactions.

He Q, Jiang X, Zhou X, Weng J. He Q, et al. Among authors: zhou x. J Hematol Oncol. 2019 Dec 18;12(1):139. doi: 10.1186/s13045-019-0812-8. J Hematol Oncol. 2019. PMID: 31852498 Free PMC article. Review.

7

Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer.

Lin M, Yao W, Xiao Y, Dong Z, Huang W, Zhang F, Zhou X, Liang M. Lin M, et al. Among authors: zhou x. Bioengineered. 2021 Dec;12(1):6343-6353. doi: 10.1080/21655979.2021.1971507. Bioengineered. 2021. PMID: 34506231 Free PMC article.

8

Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer.

Xiao Y, Yao W, Lin M, Huang W, Li B, Peng B, Ma Q, Zhou X, Liang M. Xiao Y, et al. Among authors: zhou x. Drug Deliv. 2022 Dec;29(1):1712-1725. doi: 10.1080/10717544.2022.2079769. Drug Deliv. 2022. PMID: 35635307 Free PMC article.

9

Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways.

Lin H, Sun F, Li T, Zhang Y, Guo X, Li M, Liang M, Zhou X, Fang Z. Lin H, et al. Among authors: zhou x. Cancer Chemother Pharmacol. 2022 Dec;90(6):455-465. doi: 10.1007/s00280-022-04481-9. Epub 2022 Oct 17. Cancer Chemother Pharmacol. 2022. PMID: 36251033

10

Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.

Yi G, He Z, Zhou X, Xian L, Yuan T, Jia X, Hong J, He L, Liu J. Yi G, et al. Among authors: zhou x. Int J Oncol. 2013 Nov;43(5):1503-10. doi: 10.3892/ijo.2013.2077. Epub 2013 Aug 23. Int J Oncol. 2013. PMID: 23982736

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49,365 results

Search Page